PEP-GHK-CU • RESEARCH USE ONLY

GHK-Cu

GHK-Cu (Copper Tripeptide-1) is a copper-binding regenerative peptide that stimulates collagen synthesis, tissue repair, and skin rejuvenation. This nasal formulation supports systemic anti-aging, skin vitality, and cellular repair through gentle, consistent signaling.

50 mg

Per Bottle

— 312 mcg per spray

>99%

Purity

— Third-party verified

160

Sprays per bottle

Protocol & Dosing

Use once daily, either in the morning or evening. For skin- and anti-aging–focused benefits, consistent daily use is recommended.

Starting

624 mcg (2 sprays)

Medium

936 mcg (3 sprays)

Higher

1,248 mg (4 sprays)

Cycles

May be used continuously for up to 3 months
Take 1–2 weeks off every 3 months to allow receptor and pathway reset

Key Benefits

Promotes glowing and firmer skin, supports hair growth, accelerates wound and tissue healing, reduces inflammation, enhances collagen and elastin production, and supports overall anti-aging and regenerative processes.

Guidance

Wait at least 30 minutes before or after using other peptides such as BPC-157, TB-500, or additional nasal sprays
Can be combined with KPV or BPC-157 protocols for synergistic healing effects
GHK-Cu is safe for longer-term use, but brief breaks help maintain responsiveness.
Start with 2 sprays once daily
Increase gradually only if needed
Use once daily only (do not split doses)
Do not exceed 4 sprays per day unless directed
Ideal for skin rejuvenation, hair support, wound healing, and anti-aging
Non-stimulatory and well tolerated
Pairs well with KPV, BPC-157, and other regenerative peptides when spaced appropriately

PROPRIETARY DELIVERY TECHNOLOGY

Protixa ION System™

Nasal delivery is facilitated with the Protixa ION System — a proprietary liquid ion delivery platform engineered for enhanced bioavailability, deep tissue penetration, and improved compound stability without compromising safety. Unlike carriers that rely on encapsulation, it enables direct solubilization and optimized partitioning of actives including peptides and coenzymes — no liposomes, no lipid nanoparticles, no emulsifier-dependent payloads. Built from amino acids and endogenous molecules for biocompatibility; scalable across routes that include intranasal sprays.

Lipid disruption & cation exchange

Alkyl chains intercalate into the stratum corneum lipid matrix via hydrophobic interactions, reducing cohesion and increasing permeability. Cationic components displace native ions such as Ca²⁺ within lipid lamellae, weakening structural integrity so actives pass through more efficiently.

Dual-polarity solubilization

Hydrophilic and lipophilic character solubilizes and transports a broad range of actives directly — without emulsifiers or encapsulating carriers.

Keratin modulation & partitioning

Temporarily denatures keratin within corneocytes, opening transient micro-pathways for epithelial migration. Improves solubility and skin partitioning while maintaining proprietary differentiation for IP — inspired by systems like CAGE (choline–geranic acid ionic liquids).

Superior loading vs. lipid carriers

Solubilizes actives directly instead of inefficient encapsulation. In-house studies: lipid-based carriers penetrated only ~22 μm — insufficient for meaningful absorption — whereas the Protixa ION System reaches therapeutically relevant layers.

>57× vs. saline · <10 nm (DLS)

>57× barrier penetration vs. saline in an ex vivo epithelial model (Protixa third-party data). Minimum confirmed nanoparticle size under 10 nm — mucus-penetrating ionic clusters by dynamic light scattering.

Safety, stability & distribution

ISO 10993-5 CCK-8 assay: 80–100% viability at 24 h and 48 h. Four-month room-temperature stability: 101.1–101.9% HPLC recovery — no cold chain. In vivo oral mouse study: systemic distribution across five organs at 1 hour post-dose.

Compliance · Nasal peptides

cGMP manufacturing & cryopreservation

Manufactured through Pacific Manufacturing & Design LLC — GMP-certified under NSF/ANSI 455-2 and FDA-registered (Reg. No. 15492349536). Compliant with 21 CFR Parts 11, 111, and 117. Strict quality control, validated processes, and full traceability from raw material to final product.

NSF/ANSI 455-2FDA REGISTERED21 CFR PART 11121 CFR PART 117

Third-Party COA — Every Batch

Third-party COA for every batch, ensuring consistent quality and purity. Verified through LCMS and endotoxin testing, with full traceability from raw material to final product.

LCMS CONFIRMED>99% PURITYENDOTOXIN TESTEDAXISPHARM COA